Replimune stock collapses 64% following FDA rejection
Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for a second time, sending shares down approximately 64% and forcing management into cost-cutting mode. The market is now questioning whether RP1 can still win approval and whether Replimune has enough capital to withstand a prolonged setback if […]
Replimune stock collapses 64% following FDA rejection Read More »
